Mergers & acquisitions
Alcon said the acquisition of PowerVision demonstrates its commitment to bringing advanced technology intraocular lenses to cataract patients across the globe.
The Hillerod subsidiary, Denmark Manufacturing ApS, has about 800 staffers, who are expected to continue working under Fujifilm.
On Friday, March 8, Bristol-Myers Squibb executives met with sell-side analysts to sell its $74 billion Celgene buyout.
No employees of GTx are expected to remain with the new company once the merger is complete. Oncternal will begin to trade on the Nasdaq under the ticker symbol ONCT.
Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.
Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. The meeting is when the official vote on whether Bristol-Myers Squibb will buy Celgene will take place.
San Diego-based Pacira Pharmaceuticals, a specialty pharmaceutical company, plunked down $220 million to acquire medical device company Myoscience and its non-opioid pain treatment system iovera.
For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.
Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.
Topping an offer from Billerica, Massachusetts-based company Entegris, Darmstadt, Germany-based Merck KGaA offered an unsolicited $5.9 billion to acquire Versum Materials.
PRESS RELEASES